Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras by Omidvar, Nader et al.
  
10.1128/MCB.26.10.3966-3975.2006. 
2006, 26(10):3966. DOI:Mol. Cell. Biol. 
L. Darley
Nader Omidvar, Lorna Pearn, Alan K. Burnett and Richard
 
Mediated by Ras
Inhibition of Myeloid Differentiation 
Ral Is both Necessary and Sufficient for the
http://mcb.asm.org/content/26/10/3966
Updated information and services can be found at: 
These include:
REFERENCES
http://mcb.asm.org/content/26/10/3966#ref-list-1at: 
This article cites 90 articles, 49 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 25, 2014 by Cardiff Univ
http://m
cb.asm
.org/
D
ow
nloaded from
 
 o
n
 February 25, 2014 by Cardiff Univ
http://m
cb.asm
.org/
D
ow
nloaded from
 
MOLECULAR AND CELLULAR BIOLOGY, May 2006, p. 3966–3975 Vol. 26, No. 10
0270-7306/06/$08.000 doi:10.1128/MCB.26.10.3966–3975.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Ral Is both Necessary and Sufficient for the Inhibition
of Myeloid Differentiation Mediated by Ras
Nader Omidvar,* Lorna Pearn, Alan K. Burnett, and Richard L. Darley
Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom
Received 27 July 2005/Returned for modification 6 September 2005/Accepted 20 February 2006
Hyperactivation of Ras is one of the most common abnormalities in acute myeloid leukemia. In experimental
models, Ras inhibits myeloid differentiation, which is characteristic of leukemia; however, the mechanism
through which it disrupts hematopoiesis is poorly understood. In multipotent FDCP-mix cells, Ras inhibits
terminal neutrophil differentiation, thereby indefinitely extending their proliferative potential. Ras also
strongly promotes the sensitivity of these cells to granulocyte-macrophage colony-stimulating factor (GM-
CSF). Using this model, we have dissected the signaling elements downstream of Ras to determine their relative
contribution to the dysregulation of hematopoiesis. Cells expressing Ras mutants selectively activating Raf
(Ras*T35S) or phosphatidylinositol 3-kinase (Ras*Y40C) did not significantly affect differentiation or prolif-
erative capacity, whereas Ras*E37G (which selectively activates RalGEFs) perpetuated proliferation and
blocked neutrophil development in a manner similar to that of Ras. Correspondingly, expression of constitu-
tively active versions of these effectors confirmed the overriding importance of Ral guanine nucleotide exchange
factors. Cells expressing Ras demonstrated hyperactivation of Ral, which itself was able to exactly mimic the
phenotype of Ras, including hypersensitivity to GM-CSF. Conversely, dominant negative Ral promoted spon-
taneous neutrophil development. Ral, in turn, appears to influence differentiation through multiple effectors.
These data show, for the first time, the importance of Ral in regulating differentiation and self-renewal in
hematopoietic cells.
The 21-kDa guanine nucleotide-binding Ras proteins func-
tion as membrane-bound molecular switches linking the trans-
duction of extracellular signals, via receptor and nonreceptor
tyrosine kinases, to downstream effectors regulating diverse
processes such as differentiation, proliferation, and cell cycle
progression (7). Direct activation of Ras via point mutation is
among the most common molecular abnormalities in hemato-
poietic malignancy, with an incidence of around 30% in my-
eloid leukemia and preleukemia (9, 25, 40, 58). Hyperactiva-
tion of Ras in leukemia also arises as a result of constitutive
upstream signals arising from other common abnormalities
such as those involving the Flt3 receptor (22, 46) and the
Bcr-Abl fusion (24, 90). Conversely, Ras also becomes consti-
tutively active as a result of loss of GTPase-activating protein
(GAP) activity as seen in neurofibromatosis patients, who lack
Nf1 Ras-GAP expression. These patients are at high risk of
developing juvenile myelomonocytic leukemia (JMML) (65).
Ras mutations also arise at high frequency in the preleukemic
condition known as myelodysplastic syndrome (68), character-
ized by disorders of development resulting in hyperplastic mar-
row and peripheral blood cytopenia. The association of hyper-
active Ras with both leukemia and preleukemia suggests that
Ras signaling plays an important role during hematopoietic
dysregulation and leukemic transformation.
Activated Ras genes are most commonly associated with
promotion of proliferation of a variety of cell types. However,
in the context of myeloid leukemia it has long been established
that there are no differences in the proliferative capacity of
leukemic cells compared to their normal counterparts. The
accumulation of malignant cells is instead due to the failure of
cells to undergo terminal differentiation and apoptosis (5).
There is evidence from both in vitro and in vivo models that
Ras influences the development of monocytic, erythroid, and
granulocytic cells. This is substantiated by observations of pri-
mary mouse and human cells, where Ras appears to promote
monocytic differentiation (10, 21), as well as to oppose the
differentiation of erythroid progenitors (17, 88). In addition,
neutrophilic leukocytosis has been observed with K-Ras trans-
genic mice (12), implying that Ras also affects the development
of granulocytic cells.
Another commonly observed effect of Ras on myeloid he-
matopoietic cells is the capacity to reduce the requirements
for exogenous growth factors (55, 73). This may arise in part
from the fact that many hematopoietic cytokine receptors act
through Ras, as previously reported for granulocyte-colony-
stimulating factor (G-CSF), granulocyte-macrophage CSF
(GM-CSF), and interleukin 3 (IL-3) receptors (18, 39, 72).
Cytokines are known to influence the development of hemato-
poietic cells (37), with dysregulated cytokine signaling identi-
fied as a common feature of acute myeloid leukemia, ranging
from mutational activation of growth factor receptor, as exem-
plified by the Flt3 receptor (28, 59, 89), to hyperresponsiveness
to cytokine, such as the enhanced response to GM-CSF seen
with JMML (23).
We have previously studied the effects of Ras on the multi-
potent factor-dependent cell line, FDCP-mix. These cells pos-
sess a nonleukemic phenotype, have a normal karyotype, are
factor dependent, and can be directed to undergo multilineage
development in response to cytokines (77). By changing
growth conditions (serum and cytokines), it is possible to grow
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this cell line under self-renewing conditions, such that they
retain their multipotent state; alternatively, they may be di-
rected to differentiate to form erythroid or myeloid cells. In
these cells, Ras selectively inhibits granulocytic differentiation
of neutrophils, giving rise to continued proliferation of these
partly differentiated cells. In addition, Ras also selectively in-
creases the cells’ sensitivity to GM-CSF, suggesting a link be-
tween the heightened response to this cytokine and an inhibi-
tion of differentiation (16). This phenotype therefore closely
resembles that seen with JMML, which also commonly arises
from hyperactivation of Ras (58).
As described above, the effects of Ras on myeloid develop-
ment have been well documented; however, the mechanism by
which it elicits these changes is poorly understood. Ras inter-
acts with multiple downstream effectors via a highly conserved
amino-terminal loop domain (switch I), encompassing amino
acid residues 32 to 40 (83). The three best-established effector
families are the Raf serine-threonine kinases, phosphatidylino-
sitol 3-kinases (PI3-kinases), and the Ral guanine nucleotide
exchange factor (RalGEF) family (54). In the context of my-
elopoiesis, activation of the mitogen-activated protein kinase
(MAPK) cascade via Raf has been implicated in both disrup-
tion of differentiation and changes in cytokine dependency (20,
21, 88). PI3-kinase activity has been linked with both differen-
tiation and inhibition of apoptosis (14, 20, 50) with demonstra-
tion of the synergistic requirement for Raf-mediated activation
in leukemogenesis (6). Comparatively little has been reported
regarding the role of RalGEFs in hematopoiesis, although they
have been associated with both Jak/STAT signaling and the
promotion of survival following growth factor withdrawal (33,
55). This family of effectors acts as GEFs for the Ral GTPases.
Two highly similar Ral proteins, RalA and RalB, associate with
a variety of downstream effectors (for a review, see reference
26): Sec5 and Exo84 during formation of the Exocyst complex,
which participates in delivering vesicles to the plasma membrane
(60, 61); the actin-binding protein, filamin (67); the ZO-1-associ-
ated nucleic acid-binding protein (designated ZONAB) (29), and
Ral-binding protein 1 (RalBP1), which mediates GAP activity
towards the Rho family GTPases Rac and Cdc42 (27).
Here, we show for the first time that Ral is a critical devel-
opmental regulator in hematopoietic cells. Ras promotes the
activity of this GTPase through RalGEF family members. Fur-
ther, activation of Ral is both necessary and sufficient to mimic
the inhibition of neutrophil development imposed by Ras and
is also responsible for promoting the sensitivity of these cells to
GM-CSF. The data demonstrate an as-yet-unidentified role for
Ral in controlling hematopoietic differentiation.
MATERIALS AND METHODS
Cell culture. Culturing of FDCP-mix (clone A4) cells (77) under self-renewing
conditions was carried out in Iscove’s modified Dulbecco’s medium (Sigma)
supplemented with 20% batch-tested horse serum (GibcoBRL) and 10%
WEHI-3B conditioned medium and maintained at 37°C with 5% CO2. Under
these conditions, 95% of cells exhibited an immature blast cell morphology.
Analysis of the effect of ectopically expressed genes on differentiation was carried
out as follows. Mid-logarithmic-phase cells were harvested, washed in Hanks
buffered saline solution containing 25 mM HEPES buffer (GibcoBRL), and
resuspended to 2  104 cells/ml in 5 ml of differentiation medium: Iscove’s
modified Dulbecco’s medium containing 20% batch-tested fetal calf serum,
1,000-U/ml human G-CSF, and 50-U/ml mouse GM-CSF (R&D Systems). Cells
were subcultured if necessary in the same medium. Automated May-Grunwald-
Giemsa staining (Bayer) of cytospins (20,000 cells) was carried out at day 7 (or
as indicated), and morphological assessments were made under blind conditions.
Cell proliferation was determined by viable cell counts as assessed by trypan blue
exclusion, as previously described (4).
Sensitivity to cytokines and inhibitors. To assess cytokine sensitivity, mid-
logarithmic-phase cells were harvested and washed twice in 20 ml Hanks buffered
saline solution. These were resuspended to 2  104 cells/ml in 5 ml differentia-
tion medium (as above but excluding cytokines). Recombinant mouse IL-3
(R&D Systems) at a final specific activity of 0 to 1,000 U/ml, human G-CSF (0
to 10,000 U/ml), or mouse GM-CSF (0 to 500 U/ml) was added. GM-CSF
hyperresponsiveness was assessed in the presence of constant G-CSF (50 U/ml),
since GM-CSF alone did not support the viability of these cells. Cumulative
proliferative capacity was determined by cell counts at day 5. The effect of the
Rac1 inhibitor (NSC23766; Calbiochem) was assessed by addition at the start of
the 7-day differentiation assay. The effect of PI3-kinase and MEK inhibitors was
studied on FDCP-mix Ras* cells precultured for 7 days under differentiating
conditions. These were exposed to LY294002 or PD98059 (Sigma) or U0126
(Cell Signaling Technology). Morphological and proliferative end points were
scored 3 days later as described above.
cDNA constructs. Ras effector loop domain mutants and PI3-kinase* (K227E)
(both provided by Julian Downward, London, United Kingdom) were expressed
in pLXSN. The c-Raf1 catalytic domain was expressed in the pM5 retroviral
vector (56). RalGEFs (Michael A. White, Dallas, Tex., and Johannes L. Bos, The
Netherlands) and constitutively active and inhibitory RalA constructs (Chris J.
Marshall, London and David Wynford-Thomas, Cardiff, Wales) were all sub-
cloned into the retroviral expression vector pBABE-puro. RalB, RalA Q72L,
RalA
Q72L CAAX
, and the RalA effector loop domain mutant (RalAQ72L D49E,
RalA
Q72L D49N
, and RalAQ72L N11) constructs, all in pBABE-puro, were kindly
provided by Christopher Counter (Duke University Medical Center).
Retrovirus infection. FDCP-mix-Ras* and neomycin control lines were cre-
ated as previously described (16). The remaining lines were created via the
generation of replication-defective amphotropic retrovirus by transient transfec-
tion of the Phoenix-Ampho packaging line (American Type Culture Collection).
This was subsequently used to infect the parental FDCP-mix line as described
below. Non-tissue-culture 24-well plates were treated with 15 g of RetroNectin
(TaKaRa Biochemicals) per well and incubated at room temperature for 2 h.
RetroNectin was replaced by 1% bovine serum albumin, and incubation was
carried out for 30 min for blocking. The blocking solution was replaced by 400 l
of retroviral supernatant together with 105 cells at semilogarithmic growth phase
in 1.5 ml of culture medium. This was incubated overnight at 37°C with 5% CO2,
after which the infection procedure was repeated using fresh retroviral superna-
tant. Following infection, antibiotic selection was carried out in the presence of
puromycin (2 g/ml) or neomycin (800 g/ml).
Activation assays and Western blotting. Cells were lysed in 50 mM Tris (pH
7.4), 1% NP-40, 15% glycerol, 200 mM NaCl, 5 mM MgCl2, 5 mM NaF, 1 M
leupeptin, 0.1 M aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Deter-
gent-insoluble material was removed by centrifugation (16,000  g at 4°C for 20
min). Activation sensitive pull-down assays were carried out using the binding
domains of RalBP1 (amino acids 397 to 518) and PAK (amino acids 1 to 252)
(both were kindly provided by Chris J. Marshall, London, United Kingdom),
which specifically interact with active GTP-bound forms of Ral and Rac/Cdc42
proteins, respectively, essentially as described previously (71, 86). Glutathione
S-transferase-binding domain-coupled beads were prepared by mixing at 4°C for
1 h, while the pull-down was carried out by mixing with the whole-cell lysate for
45 min. GTP proteins were eluted using 2 reducing sample buffer, boiled for 5
min at 95°C, and assessed by Western blotting (12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis). Comparative total protein content was de-
termined by parallel Western blotting of the whole-cell lysates. Immunoprobing
was carried out using the following antibodies: Ras G12V-sensitive monoclonal
(Calbiochem), pMek1/2 (#2354), pErk1/2 (#4695), and pAkt/PKB (#9271), all
from Cell Signaling Technology and RalA (BD Transduction Laboratories),
Rac1 (Upstate Biotechnology), and Cdc42 (Santa Cruz Biotechnology).
RESULTS
Activation of Ral guanine nucleotide dissociation stimulator
(RalGDS) mediates Ras-induced inhibition of differentiation.
FDCP-mix cells undergo either self-renewal or differentiation,
depending on the presence of hematopoietic growth factors. In
the presence of G-CSF plus GM-CSF, these cells undergo
predominantly neutrophil development, culminating in termi-
nal differentiation and growth arrest. Expression of mutant
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Ras (Ras*) strongly inhibits the capacity of these cells to un-
dergo terminal neutrophil development under these conditions
(Fig. 1A and E). To determine which downstream targets of
Ras influenced the development of these cells, we repeated
these experiments using cells expressing effector mutants of
Ras. Selective activation of Raf (Ras*T35S) or PI3-kinase
(Ras*Y40C) did not significantly affect differentiation capac-
ity; these cells consequently underwent terminal neutrophil
development and growth arrest. In contrast, Ras*E37G (selec-
tively activating RalGEFs-phospholipase C [PLC]) inhibited
neutrophil development (Fig. 1A), with concomitant increase
in proliferation capacity (Fig. 1B). This observation was not
due to the relative overexpression of Ras*E37G, as demon-
strated by Western blotting (Fig. 2A); indeed, normalized ex-
pression of Ras*E37G was marginally lower than that of
Ras*T35S or Ras*Y40C. Therefore, the Ras*E37G mutant is
sufficient to replicate the antidifferentiation phenotype result-
ing from activation of Ras.
The Ras*E37G effector loop domain mutant has been pre-
viously shown to interact with a group of guanine nucleotide
exchange factors for the Ral GTPase (e.g., RalGDS and Rlf)
(84), as well as the phosphoinositide-specific PLC (15, 45, 75).
However, PLC RNA is undetectable in FDCP-mix cells, as
assessed by reverse transcription-PCR (data not shown), sug-
gesting that RalGEFs were the principal target in this context.
To substantiate the data obtained with effector mutants, we
repeated these experiments using constitutively active effectors
of Ras. Consistent with the Ras effector mutant data, consti-
tutively active forms of the RalGEFs (RalGDS and Rlf) were
able to mimic the effects of Ras* under differentiating condi-
tions (Fig. 1C). Interestingly, RalGDS-CAAX was more effec-
tive in inhibiting differentiation than Ras* itself. As expected,
both these constructs concomitantly promoted proliferation
under differentiating conditions (Fig. 1D). Also in agreement
with the Ras effector mutant data, there was no difference in
differentiation or proliferative capacity between control cells
and those expressing Raf*. PI3-kinase* did demonstrate a
modest antidifferentiation effect, but this did not achieve sig-
nificance in this series of experiments.
As no significant difference in the development or prolifer-
ative capacity was observed with the Raf* or PI3-kinase*-
expressing FDCP-mix cells, the integrity of these constructs
was confirmed by Western blotting. As expected, expression of
Raf* strongly promoted MEK1/2 and extracellular signal-reg-
ulated kinase 1 (ERK1) and ERK2 phosphorylation (Fig. 2B).
Interestingly, Ras* itself was only marginally effective in this
regard. This may indicate that activation of these targets is
normally limited by endogenous levels of expression of Raf in
these cells; alternatively, it might also be the case that simul-
taneous activation of other effectors by Ras* suppresses acti-
vation of MEK/ERK. We also confirmed the phosphorylation
of Akt-protein kinase B (PKB) in the Ras* and PI3-kinase*–
FDCP-mix cell lines, confirming activation of this pathway.
Neither Ras*E37G nor RalGDS-CAAX gave rise to significant
activation of either Akt or ERK (Fig. 2D). Taken together,
these data confirmed the integrity of the constructs employed
FIG. 1. Differentiation and proliferation of FDCP-mix cells in the presence of Ras loss of function and constitutively active effector mutants.
Morphological scoring and proliferative expansion of FDCP-mix cells in the presence of Ras loss-of-function mutants (A and B) and constitutively
active mutants (C and D). Cells were seeded at 2  104/ml in medium containing G-CSF plus GM-CSF, and differentiation was assessed following
May-Grunwald-Giemsa staining. Significant differences versus FDCP-mix–Neo cells were defined as follows: *, P  0.05; **, P  0.01; ***, P 
0.005; ****, P  0.001. Error bars represent standard deviations from the mean of at least three independent experiments. (E) Morphology
(magnification, 400) after 7 days under differentiating conditions. Control cultures (Neo) are dominated by large segmented mature neutrophils
(n). Cells expressing Ras* either fail to differentiate (b) or give rise to immature neutrophils with doughnut-shaped nuclei characteristic of mouse
metamyelocytes (m); these cells retain proliferative capacity (16). Macrophage differentiation is unaffected (mac).
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and indicated that constitutive Raf and PI3-kinase signaling
appears to have little influence on neutrophil development of
FDCP-mix cells. Furthermore, these data for the first time
suggest a significant role for RalGEFs in regulating neutrophil
differentiation.
The activity of RalGEFs in mediating the inhibition of neu-
trophil differentiation suggests that the modulation of Ral ac-
tivity may be intrinsic to the observed phenotype. We therefore
assessed RalA activity using the activation-sensitive glutathi-
one S-transferase–RalBP1–RalBD probe. The level of Ral-
GTP was elevated in FDCP-mix cells expressing Ras*, Rlf-
CAAX, and RalGDS-CAAX (Fig. 2D). This observation
demonstrates that Ras as well as the RalGEF molecules (Rlf
and RalGDS) results in activation of Ral in these cells, which
is consistent with a role for Ral in mediating the effects of Ras.
Active Ral is necessary and sufficient for dysregulated my-
elopoietic development. The above data indicate a correlation
between active Ral and dysregulated hematopoiesis in FDCP-
mix cells. To substantiate whether Ral is necessary and/or
sufficient to inhibit neutrophil differentiation, we examined the
effect of activated and dominant negative versions of RalA.
The constitutively active Ral mutants used were that which is
insensitive to Ral-GAP activity (mutated at Q72L) and the
“fast-cycling” mutation (F39L) (52, 53, 70). Both RalA mu-
tants examined mimicked the blocked development and in-
creased proliferative capacity demonstrated by FDCP-mix-
Ras* (Fig. 3A). This was also associated with increased
proliferative capacity (Fig. 3B). The effects of dominant neg-
ative RalA constructs on the parental FDCP-mix cells substan-
tiated these observations. Expression of dominant negative Ral
(RalBP1-RalBD) in conjunction with Ras* abrogated the ca-
pacity of Ras* to inhibit differentiation and promote differen-
tiation (Fig. 3A and B). Expression of dominant negative Ral
constructs alone (RalBP1-RalBD or RalA S28N) promoted
spontaneous differentiation of FDCP-mix cells grown under
self-renewing conditions (IL-3) compared to the empty vector
control line (Fig. 3C and D). Interestingly, these constructs
also promoted monocyte differentiation. Therefore, constitu-
tive inhibitory RalA is able to compromise the self-renewing
capacity of FDCP-mix cells, resulting in spontaneous develop-
ment. Recent work has demonstrated functional differences
between the roles of RalA and RalB in the transformation of
human cells (51). We therefore examined the possibility that
there may also be differences in the capacity of these proteins
to affect hematopoietic differentiation by repeating these ex-
periments with the corresponding constitutively active RalB
mutants. In this context, however, we found RalB to be just as
effective as RalA (Fig. 3E and F).
Together, these data suggest that activation of RalA (or that
of RalB) directly inhibits neutrophil differentiation and that its
activity is necessary to maintain FDCP-mix cells in a self-
renewing state.
Like Ras*, both RalGDS-CAAX and RalA F39L enhance
GM-CSF sensitivity. Previously, it was shown that the block in
neutrophil development in this model was associated with an
increased sensitivity to GM-CSF and that the block in devel-
opment was dependent upon the continued presence of this
cytokine (16). To establish the possible role of the downstream
effectors of Ras in augmenting cytokine responsiveness, the
growth of the aforementioned cell lines was examined by dose-
response assays. We observed that expression of RalGDS-
CAAX promoted hyperresponsiveness to GM-CSF in a man-
ner similar to that seen with cells expressing Ras* (P  0.01)
(Fig. 4A). Similarly, cells expressing constitutively active Ral
(RalA F39L) also replicated the increase in GM-CSF sensitiv-
ity seen in Ras* (Fig. 4B). In contrast, the absolute require-
ment of all these cell lines for exogenous IL-3 remained, with
no significant difference in the dose-response data between
Ras loss-of-function mutants (data not shown) or constitutively
active mutants versus control cells (Fig. 4C). The data suggest
that expression of Ras* selectively increased the sensitivity to
GM-CSF and that both increased sensitivity to GM-CSF and
differentiation arrest are mediated via the Ral pathway.
Role of downstream effectors of Ral in the inhibition of
neutrophil differentiation. Mutants of Ral which have im-
FIG. 2. Expression and activity of effector mutants of Ras and
constitutively active downstream targets of Ras. (A) Mutant Ras ex-
pression was probed using a mutant H-Ras-specific antibody. (B) Raf
activity was investigated using the phosphorylation-specific antibodies
to MEK1/2 and ERK1/2; (C) PI3-kinase activity was assessed using a
pAkt/PKB antibody. (D) The effect of constructs activating RalGDS/
Ral on Erk1/2 and pAkt/PKB activity was similarly determined.
(E) Ral activity was determined using the GTP-sensitive probe as
described in Materials and Methods. Results are representative of two
independent experiments.
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paired capacity to activate effectors downstream of Ral have
been previously described; deletion of the N-terminal amino
acids (RalAN11) reduces phospholipase D1 binding (41), the
RalAD49E mutant is defective in binding Sec5 and Exo84
(60, 61), and the RalAD49N mutant has diminished affinity for
RalBP1 (11). We examined the phenotype conferred by con-
stitutively active (RalAQ72L) versions of these mutants to in-
dicate the contribution of these Ral effectors to the dysregu-
lation of hematopoiesis. A mutant lacking the biologically
essential CAAX motif acted as the negative control in these
experiments. Each mutant appeared to be expressed at similar
levels against the relatively high endogenous levels of RalA in
these cells (Fig. 5A). Compared to RalAQ72L, we found that
each of the effector mutants compromised the activity of con-
stitutively active RalA in the inhibition of neutrophil differen-
tiation (Fig. 5B). Correspondingly, none of the effector mu-
tants retained any capacity to promote the proliferation of
these cells under differentiating conditions (Fig. 5C). In com-
mon with RalAQ72L, these mutants did not affect the prolifer-
ative rate of these cells under self-renewing conditions (data
not shown). The simplest interpretation of these data is that
multiple effectors of Ral contribute towards its ability to inhibit
differentiation and promote self-renewal of hematopoietic cells.
Given that activation of one of these Ral effectors, RalBP1,
has been previously associated with inhibition of differentiation
(32), we investigated the individual contribution of this effector
to the observed inhibition of differentiation. Activation of
RalBP1 functions as a GAP towards the Rho-related proteins
Rac and Cdc42. Hyperactivation of Ral by Ras should there-
fore result in negative regulation of Rac1 and Cdc42 activity if
these proteins are in fact a target of Ral in this context. We
therefore examined the active-protein levels via binding-do-
main pull-down assays. This analysis revealed that whereas
control FDCP-mix cells (Neo) expressed these Rho-related
proteins in their active (GTP-bound) state, the lines expressing
Ras* and RalGDS-CAAX were almost completely deficient in
GTP-bound Rac1 and Cdc42 (Fig. 6A). The comparative dif-
ference in expression of these GTP-bound proteins between
the Rlf-CAAX and RalGDS-CAAX lines showed that the lat-
FIG. 3. Effect of RalA and RalB mutants on the development of
FDCP-mix cells. (A and B) The effect of constitutively active mutants
(F39L and Q72L) of RalA on the development of FDCP-mix cells and the
effect of dominant negative RalA (RalBP1-RalBD) on FDCP-mix cells
coexpressing Ras* are shown; conditions are as described in the legend
to Fig. 1. (C) Spontaneous differentiation under self-renewing conditions
of FDCP-mix cells expressing dominant negative RalA constructs alone.
(D) Corresponding morphology of cells grown under self-renewing condi-
tions is shown. Control cells (pBABE-puro) demonstrate a uniform blast
cell appearance, while RalA S28N cells exhibit a variety of differentiated
forms including mature neutrophils (n), macrophages (mac), and disin-
tegrating forms of segmented neutrophils (a). Morphology was scored as
described in Materials and Methods. (E and F) Effect of constitutively active
mutants of RalB on FDCP-mix cells; conditions are as described in the legend
to Fig. 1. Significant differences versus FDCP-mix–Neo cells are indicated as
follows: *, P 0.05; **, P 0.01. Error bars represent standard deviations
from the mean of at least three independent experiments.
FIG. 4. GM-CSF hypersensitivity in FDCP-mix cells is mediated
via the Ral pathway. Dose-response curves with GM-CSF (A and B)
and to IL-3 (C) are shown. Cell growth was assessed after 5 days of
culture with the indicated concentrations of cytokines. Significant dif-
ference versus FDCP-mix-Neo cells is indicated as follows: **, P 
0.01. Error bars represent standard deviations from the mean of at
least three independent experiments.
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ter effector more closely mimicked the effects of Ras*. Inter-
estingly, we also observed that PI3-kinase* weakly reduced
GTP-bound levels of Rac1 and Cdc42. These observations
correlate with the weak inhibitory effect on neutrophil devel-
opment described above (Fig. 1C) and suggest a degree of cross
talk from this effector.
Recently, a highly selective cell-permeable inhibitor for
Rac1, NSC23766, has become available (31); we therefore
examined the influence of Rac1 inhibition on FDCP-mix de-
velopment. NSC23766 strongly inhibited neutrophil differenti-
ation in a dose-dependent manner (Fig. 6B), however, at
higher doses, it was also antiproliferative (Fig. 6C). Neverthe-
less, the degree of inhibition at low doses was at least consis-
tent with a role for Rac1 inactivation in mediating part of the
antidifferentiation effects of Ras.
PI3-kinase activity is required to maintain the differentia-
tion block imposed by Ras. Experiments using activated effec-
tors and effector mutants of Ras suggested that hyperactivation
of PI3-kinase was not sufficient to block neutrophil differenti-
ation; however, the data in Fig. 6A and 1C indicated that
FIG. 5. Role of downstream effectors of Ral in the inhibition of
neutrophil differentiation. (A) The expression of RalA effector loop
domain mutants in FDCP-mix cells by immunoblotting is shown; the
corresponding expression of actin is also shown as a loading control.
Morphological scoring after 7 days under differentiating conditions
(B) and corresponding proliferative expansion (C) of FDCP-mix cells
in the presence of RalA effector loop domain mutants (conditions
are as described in the legend to Fig. 1) is shown. Significant
differences versus FDCP-mix-RalAQ72L CAAX cells are indicated as
follows: *, P  0.05; **, P  0.01. Error bars represent standard
deviations from the mean of three independent experiments.
FIG. 6. Expression and activity of Rac1 and Cdc42 and effect of
inhibition of Rac1. After 7 days in the presence of G-CSF plus GM-
CSF, normalized protein from whole-cell lysates of the indicated
FDCP-mix cell line was assayed. A total of 10% of the lysate was
assessed for total protein levels by Western blotting; the remainder was
immunoprecipitated with PAK-Rac-binding domain. Immunoprobing
was carried out using the Cdc42 polyclonal and Rac1 monoclonal
antibodies. (A) The results shown are representative of two indepen-
dent experiments. (B) The effect of the Rac1 inhibitor, NSC23766, on
neutrophil differentiation; conditions are as described in the legend to
Fig. 1. (C) Corresponding effect of the Rac1 inhibitor, NSC23766, on
cell growth after 7 days in culture. No significant cell death was ob-
served in any of the conditions used (5% of cells). A significant
difference versus vehicle alone treated FDCP-mix cells is indicated as
follows: *, P  0.05; **, P  0.01. Error bars represent standard
deviations from the mean of three experiments.
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PI3-kinase activity did participate in this process. We therefore
examined the requirement for both PI3-kinase activity, as well as
MAPK activity, to maintain the differentiation block imposed by
Ras. We treated differentiation-blocked FDCP-mix–Ras* cells
with inhibitors to either PI3-kinase or MEK. Inhibition of PI3-
kinase with LY294002 strongly promoted differentiation (Fig. 7A)
and correspondingly inhibited proliferation (Fig. 7B), indicating
that the maintenance of the differentiation-inhibited phenotype
was dependent on PI3-kinase activity. In contrast, inhibition of
MEK with PD98059 had no significant effect on the differentia-
tion of these cells, despite the fact that it inhibited their prolifer-
ation (Fig. 7B). The MEK1/2 inhibitor, U0126, gave similar re-
sults (data not shown). These indicate that PI3-kinase activity is
required to maintain the antidifferentiation phenotype elicited by
Ras. Correspondingly, MAPK activity does not appear to play a
role in inhibiting the differentiation of these cells. These data are
consistent with the lack of influence of activated Raf and the
corresponding effector mutant of Ras on neutrophil development
(Fig. 1). They are also consistent with the fact that Ras itself does
not constitutively promote MAPK activity in this context (Fig. 2).
DISCUSSION
Although there is some understanding of the processes
which regulate hematopoietic differentiation at a transcrip-
tional level, little is known of the intracellular events which
regulate this developmental programming. These are influ-
enced by environmental factors such as the presence of cyto-
kines and stromal factors (3). Since many of these environmen-
tal signals are transduced via Ras proteins, it is perhaps not
surprising that in cells expressing constitutively active Ras
these signals become “distorted,” leading to a dysregulation of
development. Previous work from our laboratory established
that mutational activation of Ras selectively inhibited neutro-
phil development and concomitantly increased sensitivity to
GM-CSF (16). In this study, we identify the downstream tar-
gets of Ras, which mediate these changes in developmental
programming and cytokine responsiveness. We examined
three well-characterized Ras effector proteins (Raf, PI3-ki-
nase, and RalGEFs) and their related pathways (54). Studies
using effector mutants of Ras indicated that it was RalGEF
signaling which was shown to have the predominant role in the
dysregulated development mediated by Ras. Although the use
of these effector mutants allows the dissection of signaling
activity in a relatively nonmanipulative manner (in that the
expression level and activity of downstream targets are not
artificially altered), the use of these mutants does not provide
direct evidence of the interacting proteins (including as-yet-
unidentified effectors). We therefore repeated these experiments
using constitutively active Raf, PI3-kinase, and RalGEFs. Data
from these experiments replicated the phenotypes of the corre-
sponding effector loop domain mutants, both substantiating our
initial observations and definitively identifying RalGEFs as the
key effector in mediating this phenotype. Although the involve-
ment of these RalGEFs or their putative effector, Ral, during
hematopoiesis has not been previously reported, their ubiquitous
expression has been identified within the relevant compartments
including bone marrow, spleen, and thymus (2, 85).
The involvement of the RalGEFs implicated Ral signaling as
being important for neutrophil development in FDCP-mix
cells. Use of the activation-specific probe for Ral confirmed the
association of increased Ral activity with the expression of Ras
and RalGEFs. Furthermore, we also demonstrated that pro-
moting the activity of Ral by using constitutively active mutants
was itself sufficient to block neutrophil development. Con-
versely, expression of dominant negative Ral promoted differ-
entiation of FDCP-mix cells even when cultured under self-
renewing conditions. These data suggest that the activity of this
GTPase is essential to maintain the self-renewing potential of
these cells. Given that a universal property of leukemic blasts
is their capacity for self-renewal, these data suggest that Ral
activity may be an important factor in maintaining the self-
renewing potential of leukemic cells. This is the first demon-
stration of a role for Ral in hematopoietic differentiation and
self-renewal; however, Ral has been previously implicated as a
developmental regulator in Drosophila melanogaster eye (57)
and in inhibiting differentiation of PC12 cells, as defined by
neurite outgrowth (32). In the context of cellular transforma-
tion, Ral activity has a long-established role (30, 80, 84); this
role may be more significant in human cells (35, 69). The
function of Ral activity has been assessed in a variety of con-
texts: a RalGDS knockout study has shown a role for Ral
activity in inhibiting apoptotic death (34), and distinct func-
tions for RalA and RalB have been identified, with RalB being
required for suppression of apoptosis while RalA is required
for anchorage-independent proliferation (13). RalA has also
been reported to have a preferential affinity for exocyst com-
plex (74), although it is possible that in the context of overex-
pression of Ral, differences in affinity may not be limiting.
Recent work has also identified a dominant role for RalA in
the transformation of human cells (51).
We have not so far established how Ral ultimately inhibits
neutrophil development. Studies employing effector mutants
FIG. 7. Effect of inhibition of PI3-kinase and MEK on the differ-
entiation of FDCP-mix Ras* cells. (A) Differentiation-blocked FDCP-
mix Ras* cells (day 7 cells cultured under differentiating conditions at
2  105 cells/ml) were treated with inhibitors LY294002 (LY) and
PD98059 (PD) at the indicated M concentrations, their differentiated
status was assessed 3 days later. (B) Cell growth was determined at the
same time point. None of the experimental conditions resulted in
significant cell death (5% of cells). Significant differences versus
untreated FDCP-mix-Ras* are indicated as follows: *, P  0.05. Error
bars represent standard deviations from the mean of three indepen-
dent experiments.
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of Ral suggest that this GTPase influences neutrophil devel-
opment through a variety of effectors. Previous work has
shown that all the established Ral effectors are able to influ-
ence differentiation. Increase in phospholipase D1 activity is
closely associated with neutrophil differentiation (64, 66). The
exocyst complex has not yet been directly linked with hemato-
poietic development, but it is associated with neurite out-
growth in neuronal and PC12 cells (47, 82). In both these
instances, however, the increase in effector activity is associ-
ated with promoting rather than inhibiting differentiation.
RalBP1 is thought to act as a GAP (or negative regulator)
towards the Rho superfamily of Rac1/Cdc42 GTPases (43).
These Rho family proteins have been previously associated
with differentiation of epithelial cells (78), myoblasts (19, 36,
76), dendrites (49), and dorsal root ganglia (42, 81) and during
PC12 neurite formation (87). It might therefore be predicted
that increased RalBP1 activity would be associated with an
inhibition of differentiation in these contexts; in the PC12
model, there is indeed evidence that RalGEFs inhibit differ-
entiation by suppressing the activity of Rac and Cdc42 (32).
Similarly, we present evidence that inhibition of Rac1 activity
does suppress differentiation in FDCP-mix cells.
The surprisingly negligible contribution of the Raf and PI3-
kinase effectors to hematopoietic dysregulation in this study
may be due to the prevailing importance of the Ral pathway in
this context. Alternatively, optimum activation of Raf and PI3-
kinase may already be present in FDCP-mix cells; therefore,
increasing their activity via Ras may be of little significance. In
the context of the Raf effector pathway, it is interesting to note
that, as with primary leukemias (38), the presence of activated
Ras did not provoke constitutive activation of MAPK in
FDCP-mix cells; even inhibition with MAPK inhibitors failed
to influence the differentiation-inhibited status of FDCP-mix
Ras* cells. These data, together with the lack of effect of
constitutive activation of Raf, indicate that this effector is not
playing a role in the regulation of neutrophil differentiation,
although it may, as previously suggested (63), play a role in
maintaining their proliferative capacity. In contrast to Raf,
activation of PI3-kinase via the Ras*Y40C effector mutant or
the constitutively active version of this kinase did provoke a
modest antidifferentiation effect in these cells, implying that
this effector may also participate in this process. These data
were supported by the observation that inhibition of PI3-kinase
activity reversed the effect of Ras on neutrophil differentiation,
indicating that the maintenance of the antidifferentiated state
was at least dependent on PI3-kinase activity. Since Ral has
also been shown to be activated in a PI3-kinase-dependent
manner in neutrophils (62), this may indicate that multiple
effectors of Ras (RalGEFs and PI3-kinases) may converge on
this GTPase. This possibility is also supported by the observa-
tion that expression of constitutively active PI3-kinase also
suppressed Rac1 activation and, to a certain extent, Cdc42
activation. It has been suggested that PI3-kinase may partici-
pate in RalGDS activation by promoting its association with
PI3-kinase-dependent kinase 1, which in turn appears to re-
lieve autoinhibition of the catalytic domain of RalGDS (79).
A further observation of interest relates to the increased
sensitivity to GM-CSF in cells expressing constructs that di-
rectly or indirectly activated Ral. We have previously shown
that the influence of GM-CSF is crucial in maintaining the
block in differentiation, in that its withdrawal leads to sponta-
neous terminal differentiation. These observations have inter-
esting parallels with that of JMML. In JMML, 20 to 30% of
cases are associated with loss of Nf1 Ras-GAP function, lead-
ing to hyperactivation of Ras. JMML-derived progenitor cells
display a marked hypersensitivity towards GM-CSF, as shown
by CFU-GM assays (23), with a similar phenotype demon-
strated with Nf1	/	 mouse cells (8, 48). While these studies
strongly suggest that heightened sensitivity to GM-CSF in
JMML is explicitly mediated via Ras (44), there is uncertainty
as to the mechanism through which this arises. In Myb-trans-
formed Nf1	/	 murine cells, increased sensitivity appears to
arise from autocrine production of GM-CSF that was depen-
dent on Raf/MEK/ERK signaling (20). However, only around
50% of JMML patients demonstrate excessive GM-CSF pro-
duction, despite the fact that they universally show increased
sensitivity to this cytokine. In the model described here, we
could find no evidence of autocrine production of this cyto-
kine, also suggesting that additional and/or alternative mech-
anisms exist. In this context, it will be of interest to determine
the activation state of Ral in Nf1	/	 cells and whether their
heightened response to GM-CSF is dependent on the activity
of this GTPase.
Despite the variety of approaches aimed at dysregulated Ras
signaling in a clinical setting (1), none has proved particularly
effective so far. Therefore, the identification of alternative
pharmacological targets may be of significance. In the context
of leukemia, such a target may be the small GTPase Ral.
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